Whole lung tissue engineering is a relatively new area of investigation. In a short time, however, the field has advanced quickly beyond proof of concept studies in rodents and now stands on the cusp of widespread scale up to large animal studies. Therefore, this technology is ever closer to being directly clinically relevant.
INTRODUCTION
Currently, the only curative option for patients with end-stage lung disease is lung transplantation. However, 20% of patients waiting for a transplant die on the waiting list [1] , and those patients that do receive a lung transplant face lifelong immunosuppression and high rates of graft failure. Despite 50 years of experience [2] , the 10-year mortality in lung transplant recipients remains above 60% [3] . To address this need, several teams, including our own, are working to engineer whole lungs [4 && ,5 && , 6, 7] ; the goal is to create lungs on demand from a patient's own cells, thereby increasing organ availability and minimizing the need for post-transplantation immunosuppression. Such an achievement would have a deep impact on the care of terminally ill pulmonary patients.
In this article, we describe recent progress in whole lung regeneration and highlight key scientific and clinical challenges to translating this work from the laboratory to the operating room. We discuss ongoing efforts to optimize three-dimensional (3D) scaffold production, to identify key lung stem and progenitor cells for organ regeneration, and to engineer bioreactor culture chambers to grow whole organs ex vivo. We review techniques to evaluate engineered lung function and highlight the need for standard practices and nondestructive sampling methods. Finally, we briefly discuss considerations for evaluating engineered human lungs in large animals and, eventually, in the clinic.
SCIENTIFIC FOUNDATIONS OF LUNG ENGINEERING
Three components are required to engineer a tissue in vitro: first, a scaffold to support cell attachment and growth; second, cells with which to populate the scaffold; and third, a bioreactor that provides
Scaffolds for lung regeneration
Decellularization is a process by which physical, chemical, or biological means are used to remove the cellular components of a tissue or organ, leaving the overall structure of the organ intact [8] . Using freeze-thaw cycles, enzymatic digestion [9] , or detergents such as Triton X-100 or sodium deoxycholate [10] , researchers obtain a 3D biological scaffold that retains architectural, biochemical, and mechanical properties of native tissue. The microscopic extracellular matrix (ECM) proteins and associated carbohydrates that remain after decellularization are biologically active and serve as both a surface on which cells can grow and as a signaling platform for these cells. Adhesion sites inherent in matrix proteins form molecular 'zip codes' that are important for regulating cell attachment, migration, proliferation, and even differentiation [11] . Therefore, decellularization must balance removal of potentially antigenic cellular constituents with the maintenance of these underlying ECM proteins. Protocols initially devised for whole rat lungs have been successfully scaled up for use with porcine [12, 13] 
KEY POINTS
There is an unmet need for additional lungs available for transplant.
Functional three-dimensional lung tissue can be engineered using a decellularized extracellular matrix scaffold, key endogenous cell types, and a biomimetic bioreactor culture chamber.
In order to engineer clinically useful lung tissue on a large scale, key stem and progenitor cell advances must be made; namely, the identification and derivation of lung cells that can populate a pulmonary scaffold and confer organ function are critical milestones that have yet to be met.
Criteria for and assays to evaluate the function of derived cells, engineered tissue, and preimplant constructs must be a focus of both engineers and clinicians.
Interdisciplinary large animal work is indispensible to the advancement of engineered organs from the laboratory to the clinic. treatment will be most efficacious and tractable for eventual clinical use has yet to be reached.
Cells for scaffold repopulation
The appropriate choice of cell types for seeding the decellularized scaffold remains the biggest uncertainty in the path toward regenerating a lung in vitro. The designated stem or progenitor cells must proliferate sufficiently to repopulate the surface area of a full set of human lungs (100 m 2 ), must confer the key functions of the lung, and must renew over time and in response to injury. Ciliated and goblet cells in the proximal airways, alveolar type I (ATI) and type II (ATII) cells in the distal alveoli, and vascular endothelial cells in arterial, venous, and capillary networks are indispensible. In addition, alveolar lipofibroblasts and other supporting cells of mesenchymal lineage will likely be necessary. Together, these cells confer: a thin alveolar epithelial layer that enables gas exchange, an alveolar-capillary barrier that prevents translocation of blood or blood components into the air spaces, surfactant to prevent alveolar collapse, host defense in the form of ciliated and mucus-producing cells, and a patent vasculature that produces vasoactive and antithrombotic substances such as endothelial nitric oxide synthase (eNOS) and prostacyclin.
To balance an effective outcome with the practical considerations of working with a large number of cell types, investigators must place a high premium on selecting a minimum number of essential progenitors. In the proximal lung, for example, p63þ/Krt5þ basal cells give rise to both ciliated and secretory epithelial cells [17] . Distally, integrin a 6 b 4 þ alveolar epithelial cells, club cells, and type II alveolar epithelial cells are candidate progenitors [18] [19] [20] [21] . Further work is needed to define these cell populations in the human lung, because many were first identified in murine models. Selected endogenous progenitors may ultimately serve as targets for induced pluripotent stem (iPS) cell differentiation, to enable immunologic compatibility with the intended recipient. Thus far, directed differentiation protocols have produced proximal airway cells from human embryonic stem cells [22] and distal lung cells from human iPS cells [23] .
With regard to endothelial cell function, microvascular pulmonary endothelial cells may be sufficient for whole lung repopulation. However, evidence of functional heterogeneity among pulmonary endothelial cells suggests that effective function may necessitate both microvascular and macrovascular endothelial cells [24] . Similarly, one or more types of mesenchymal/stromal cells should be included to support scaffold maintenance and epithelial health through secretion of matrix components and growth factors [21] . The addition of stromal cells to whole lung cultures, for example, enhances the engraftment of transplanted embryonic epithelial lung progenitor cells in mice [25 & ] and improves the barrier function of an endothelialreseeded decellularized lung [26] .
Bioreactor designs
Construction and use of bioreactors that provide sterile, sealed environments for organ culture and that incorporate pumps, fluid reservoirs, and electronics to apply and monitor organ perfusion and ventilation (Fig. 2) are in the early stages of development [27,28,29 & ]. Work to evaluate parameters such as vascular perfusion rate, tidal volume, respiratory rate, or peak 'intrathoracic' (i.e., intrabioreactor) and intra-alveolar pressures during culture are required, as these stimuli are critical for proper lung development. Vascular perfusion provides shear stress that enhances the expression of endothelial cell-cell junctions [30] and increases expression of eNOS mRNA [31] ; insufficient or inappropriately applied shear stress results in disorganized endothelial cell-cell junctions and impaired barrier permeability [32] [33] [34] . Likewise, the amount of stretch applied to alveoli during development influences both the thickness of the alveolarcapillary barrier and the relative numbers of ATI and ATII [35] ; complete lack of fetal breathing movements results in pulmonary hypoplasia [36] . Therefore, special attention needs to be paid to these aspects of whole organ engineering.
FORM VS. FUNCTION: EVALUATING THE RESULTS OF ENGINEERING EFFORTS
To date, engineered constructs have been shown to exchange gas in vivo for a matter of hours before failing because of vascular thrombus formation and incomplete barrier function. This failure mode suggests that more research is required to identify the particular cell populations required for longterm organ function. Additional functional evaluation will be especially important as cells derived from pluripotent precursors -embryonic stem and iPS cells -are increasingly incorporated into the engineered tissues.
Cellular phenotype in engineered lungs
Early studies demonstrated that implantable lung constructs could be engineered using either a combination of fetal rat lung cells and human umbilical vein endothelial cells, or mixed rat lung cells with rat lung microvascular endothelial cells [4
&& ]. When these cell populations were seeded into the airways and vasculature of decellularized scaffolds and cultured in a bioreactor for approximately 1 week, the resulting construct resembled native lung histologically. Both studies reported that the cells in the constructs displayed markers of type I and II alveolar epithelial cells, airway epithelial cells, endothelial cells, and interstitial cells. Other groups have demonstrated that less mature cell populations can also begin expressing markers of type II alveolar cells when cultured on decellularized matrix [6, 37] .
However, characterization of these cells relies largely on visual assessment of morphology and immunofluorescent staining of surface and intracellular markers, and assessment of gene expression by reverse transcription polymerase chain reaction (RT-PCR). Other than the use of fluorescently tagged surfactant to demonstrate surfactant recycling [38] , little functional evaluation has been applied to the cells derived by these protocols, despite the fact that functional evaluation at the cellular level is an integral part of research, regulatory practice and use, and of establishing eventual manufacturing standards.
Engineered organ function ex vivo
The function of engineered tissues must be evaluated during culture and prior to implantation. However, current criteria for donor lungs for transplant are not sufficient to evaluate tissue-engineered organs [39] . To ensure that engineered lungs satisfy minimal structural and functional parameters prior to implantation, we must develop reliable and nondestructive methods to evaluate tissue integrity and function. These parameters must include assessment of alveolar-capillary barrier function, gas exchange, respiratory mechanics, and vascular patency.
Assessment of lung scaffold structural integrity by bronchoscopy and microcomputed tomography (micro-CT) [ [6, 37] , and elastance [6, 37] . All studies showed significant differences between native and decellularized lung; most [5 && ,6,37] showed persistent differences between engineered and native lung. However, each of these studies employed slightly different methods, including volume-controlled continuous ventilation to obtain dynamic compliance values [4 && ], direct measurements of pressure and volume to obtain quasi-static compliance [35] , and pressure-controlled ventilation [6, 37] . Standardizing these assessments would facilitate direct comparison of engineering techniques and outcomes. Long-term, such assessments will be critical for decisions regarding implantation.
Techniques to measure the ability of engineered lung vasculature to prevent thrombosis have yet to be devised. Assays that evaluate the ability of the engineered vasculature to inactivate factor Xa and thrombin [42 & ] or report of a minimum time to thrombosis for heparinized or unheparinized whole blood could be useful in determining how the construct would fare in vivo.
Engineered organ function in vivo
To date, the sum of in-vivo evaluation of implanted engineered organs includes pulmonary artery blood gas measurement [ ], in combination with bronchial-alveolar lavage (BAL). BAL can help to determine whether airway fluid is hydrostatic in origin or due to compromised barrier integrity [44] [45] [46] . Additional metrics such as right heart, pulmonary capillary wedge, and central venous pressures, as well as ventilation/perfusion (V/Q) scans will be crucial to evaluating engineered lung function in vivo. A standard protocol for postoperative follow-up incorporating many of these techniques should be devised well in advance of any large-mammal trial.
PRACTICAL CONSIDERATIONS FOR CLINICAL USE: LARGE ANIMAL EXPERIMENTS AND CLINICAL PERSPECTIVE
Ultimately, 'performing a clinical trial using an agent about which all properties are known is, in fact, rarely possible' [47] , however, large-animal models are better at predicting therapeutic responses than rodent models and so must be pursued. Pigs and nonhuman primates in particular would support eventual regulatory approval to test engineered organs in humans, and pig models have been used to investigate and validate ex-vivo lung perfusion techniques [48] . Pig scaffolds may also serve as a substrate for human cells, possibly providing an avenue from laboratory to clinical work [7,15 & ,49-51] . As a specific animal model of a relevant human disease, CFTR-null and CFTR-DF508 piglets have been produced and may be of use in evaluating the effectiveness of engineered lungs for transplant into pulmonary patients [52, 53] . Alternatively, investigation of the ability of an engineered lung transplant to reduce mortality following acute or chronic lung injury may be more tractable [54, 55] .
In either instance, we must assemble a team experienced in performing complicated thoracic surgeries and follow-up care in the setting of compromised lung function. As the first human patients are likely to have end-stage respiratory failure, protective ventilator strategies and extracorporeal circulation may prove useful for managing the patient perioperatively [56 & ]. These tools may also be helpful postoperatively, as first-generation engineered constructs may not respond to pharmacologic intervention in the same way as native tissue, or may present unforeseen complications. As such, specialized protocols and expertise will be critical to safe clinical translation.
As cell-based therapies for lung disease move forward, it will be increasingly important that we identify the patient population most likely to benefit from this technology. Decompensating cystic fibrosis patients and end-stage pulmonary disease patients could both benefit from engineered lungs [57] [58] [59] . However, the physiology, biology, and age of each of these groups at the prospective time of transplantation are very different. Because the ideal lung construct will be made from a patient's own cells, and the protocol for transplant will necessarily take into account age and comorbidities, we have to begin thinking about who will likely be the first candidates for transplant. Such complex decisions will require input from anesthesiologists, pulmonologists, intensivists, cardiothoracic surgeons, and ethicists in collaboration with the biological engineers currently spearheading this work.
Finally, it will be important to monitor for acute status changes necessitating additional intervention or alternate therapy -in addition to standard complications such as immune rejection and organ failure, iPS-cell derived tissues have shown some potential for teratoma formation [60, 61] . As this would be a dangerous outcome, techniques should be adopted to both minimize and allow the early detection of such complications. Both tumor surveillance and accrual of long-term outcome data will be important for safety evaluation and to provide data for continued scientific refinement.
CONCLUSION
Six years after the first reports of engineered whole lung, the field has extended beyond proof of concept and must now grapple with details regarding cell source and type and refinement of culture conditions to enable proper tissue organization. Functional evaluation of the cells ultimately derived for use in scaffold repopulation and delineation of functional criteria for the overall construct are pressing issues that will be critical to advancement of this work. In tandem, careful consideration to transitioning from rodents to large animals will both improve the information that can be obtained, and will lay important groundwork for the forthcoming transition to the clinic. The inclusion of clinicians in the next stages of development is especially important as: first, they possess key areas of knowledge that can inform the design of functional assays and the selection of transplant models and patients in particular; and second, surgeons, anesthesiologists, and intensivists will ultimately constitute the team of individuals who will handle and implement the use of whole engineered www.co-anesthesiology.comlungs in the clinic. Overall, we expect that strategic and committed collaboration between clinicians, scientists, and engineers will speed the transition of this much-needed technology from the laboratory to clinical practice.
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